Skip to main content

Table 1 Demographics and Clinical characteristics of 173 patients with Behcet’s disease

From: Diagnostic value of the interferon-γ release assay for tuberculosis infection in patients with Behçet’s disease

Characteristics BD (n = 173) ATB (n = 18) LTB (n = 29) Previous TB (n = 12) Non-TB (n = 114)
Age (years, mean ± SD) 37.07 ± 14.74 36.78 ± 10.61 43.52 ± 15.23 42.75 ± 14.06 34.87 ± 14.76
Male (percentage) 114 (65.9%) 11 (61.1%) 23 (79.3%) 5 (41.7%) 75 (65.8%)
BDCAF score (median, range) 2 (0–5) 1.5 (1–5) 2 (0–5) 3 (0–5) 2 (0–5)
Clinical features of BD
 Oral ulcer 170 (98.3%) 18 (100%) 28 (96.6%) 12 (100%) 112 (98.2%)
 Genital ulcer 101 (58.4%) 15 (83.3%) 20 (68.9%) 9 (75%) 57 (50%)
 Skin lesions 101 (58.4%) 13 (72.2%) a 10 (34.5%) 10 (83.3%) 68 (59.6%)
 Erythema nodosa 53 (30.6%) 9 (50%) a 6 (20.6%) 5 (41.6%) 33 (28.9%)
 Pathergy reaction 39 (22.5%) 7 (38.9%) 7 (24.1%) 3 (25%) 22 (19.3%)
Gastrointestinal involvement 68 (39.3%) 5 (27.7%) 12 (41.4%) 5 (41.7%) 46 (40.3%)
 Vascular involvement 49 (28.3%) 7 (38.9%) 9 (31%) 3 (25%) 30 (26.3%)
 Ocular involvement 33 (19%) 4 (22.2%) 3 (10.3%) 1 (8.3%) 25 (21.9%)
 Neurologic involvement 26 (15%) 1 (5.5%) 3 (10.3%) 3 (25%) 19 (16.7%)
Treatment
 Glucocorticoid 113 (65.3%) 12 (66.7%) 22 (75.9%) 6 (50%) 73 (64%)
 Immunosuppressive agents 94 (54.3%) 7 (38.9%) 16 (55.2%) 8 (66.7%) 63 (55.3%)
Biological agents
 Infliximab/Etanercept 12 (6.9%) 2 (11.1%) 2 (6.9%) 1 (8.3%) 7 (6.1%)
  1. ATB compare with LTB; ap<0.05
  2. BD Behçet’s disease, TB tuberculosis, ATB active tuberculosis, LTB latent tuberculosis